Annual Grant Award Dollars
| Investigator | Title | Sponsor | ID | Dates | Amount |
| Raouf Samy Amin, MD | Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health | Children's Hospital of Philadelphia (National Institutes of Health (NIH)) | U01HL125295 | 7/1/2018 - 6/30/2019 | $180,816 |
| Raouf Samy Amin, MD | Upper Airway Structure and Function and risk for OSA in Children with Down Syndrome | Albert Einstein College of Medicine (National Institutes of Health (NIH)) | 311427 | 9/15/2018 - 4/30/2019 | $63,600 |
| Raouf Samy Amin, MD | Therapeutic Development Center Award | Cystic Fibrosis Foundation | CLANCY14Y0 | 1/1/2019 - 12/31/2019 | $98,524 |
| Raouf Samy Amin, MD | A Two-part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) | Cystic Fibrosis Foundation | CLANCY14K1 | 7/1/2018 - 6/30/2019 | $38,163 |
| Raouf Samy Amin, MD | Additional Research Coordinator (ARC) Award | Cystic Fibrosis Foundation | CLANCY14Y4 | 12/1/2018 - 11/30/2019 | $21,799 |
| Raouf Samy Amin, MD | A prospective study to evaluate biological and clinical efforts of significantly corrected CFTR function (PROMISE) | Seattle Children's (Cystic Fibrosis Foundation) | PROMISE-OB-18 | 3/28/2019 - 3/27/2022 | $87,486 |
| Raouf Samy Amin, MD | PATS study - Down syndrome supplement | Children's Hospital of Philadelphia (National Institutes of Health (NIH)) | 3210920619-S/PO#2001 | 7/1/2018 - 6/30/2019 | $105,949 |
| John J Brewington, MD | Sensitivity of corrected F508del CFTR to chronic beta-agonist therapy | Cystic Fibrosis Foundation | BREWIN16A0 | 7/1/2018 - 6/30/2019 | $130,000 |
| John J Brewington, MD | Pilot Development of Translational Primary Human Airway Model Systems to advance CF Care | Cystic Fibrosis Foundation | CLANCY14XX0 | 7/1/2018 - 6/30/2019 | $100,242 |
| Barbara A Chini, MD | CFF 1st and 2nd Yr Fellowship | Cystic Fibrosis Foundation | SWETLA18B0 | 7/1/2018 - 6/30/2019 | $61,750 |
| John Paul Clancy, MD | Personalizing Cystic Fibrosis Research Translation | Cystic Fibrosis Foundation | CLANCY15R0 | 7/1/2018 - 6/30/2019 | $470,000 |
| Elizabeth Kramer | Losartan as anti-inflammatory therapy to augment F508del CFTR recovery | University of Miami (Cystic Fibrosis Foundation) | SPC-000389 | 4/1/2018 - 3/31/2019 | $91,320 |
| John Paul Clancy, MD Anjaparavanda P Naren, PHD Anil Goud Jegga DVM |
Preclinical characterization of saracatinib for cystic fibrosis therapy | National Institutes of Health (NIH) | UG3 TR002612 | 9/15/2018 - 8/31/2019 | $212,000 |
| Zackary Cleveland, PHD | Validating Quantitative Magnetic Resonance Imaging Biomarkers of Idiopathic Pulmonary Fibrosis | National Institutes of Health (NIH) | R01HL143011 | 1/1/2019 - 12/31/2019 | $766,656 |
| Daniel Grossoehme | Training Research-Literate Chaplains as Ambassadors for Spirituality and Health: Phase I | Rush Medical University Center (John Templeton Foundation) | 51996 | 7/1/2018 - 6/30/2019 | $3,285 |
| Theresa Guilbert, MD-MS | ORBEX: Primary Prevention of Asthma and Wheezing in Children | University of Arizona (National Institutes of Health (NIH)) | PO 438886 | 5/1/2018 - 3/30/2020 | $263,705 |
| Theresa Guilbert, MD-MS | Vitamin D to prevent Severe Asthma Exacerbations in High-Risk Children - CCC | University of Pittsburgh (National Institutes of Health (NIH)) | 0045031 (130888-5) | 6/1/2018 - 5/31/2019 | $173,994 |
| William D Hardie, MD John Paul Clancy, MD |
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship | National Institutes of Health (NIH) | T35HL113229 | 5/1/2018 - 4/30/2020 | $72,846 |
| Yunjie Huang, PHD | Targeting ERdj4, a Novel Co-chaperone in the ER Lumen, to Rescue Mutant CFTR | Cystic Fibrosis Foundation | HUANG17F0 | 4/1/2018 - 3/31/2019 | $65,450 |
| Pramodha S Liyanage | Insights into CFTR Conformational Dynamics using single-molecule FRET in Real-time | Cystic Fibrosis Foundation | LIYANA19F0 | 5/1/2019 - 4/30/2020 | $63,100 |
| Satish K Madala, PHD | WT1 Regulation of Pulmonary Fibrosis | National Institutes of Health (NIH) | R01HL134801 | 5/1/2019 - 4/30/2020 | $393,128 |
| Satish K Madala, PHD | Therapeutic Benefit of Hsp90 Inhibition in Pulmonary Fibrosis | National Institutes of Health (NIH) | W81XWH-17-1-0666 | 9/30/2018 - 9/29/2019 | $598,677 |
| Satish K Madala, PHD | IL-31 Regulation of Immunopathology in Pulmonary Fibrosis | National Institutes of Health (NIH) | R21AG059533 | 8/15/2018 - 4/30/2019 | $245,887 |
| Gary McPhail, MD | Cystic Fibrosis Center Program Accreditation And Funding | Cystic Fibrosis Foundation | CC160-130 | 7/1/2018 - 6/30/2019 | $153,175 |
| Gary McPhail, MD | Testing the Effect of Adding Chronic Azithromycin to Inhaled Tobramycin. A randomized, placebo-controlled, double-blinded trial of azithromycin 500mg thrice weekly in combination with inhaled tobramycin study | Seattle Children's (Cystic Fibrosis Fdn Therapeutics, Inc) | TEACH-IP-15 | 9/19/2018 - 9/18/2020 | $57,257 |
| Gary McPhail, MD | Improving Outcomes in CF Patients: Toward rapid detection of P. aeruginosa | Dartmouth College (National Institutes of Health (NIH)) | R1069 | 9/20/2018 - 8/31/2019 | $25,027 |
| Gary McPhail, MD | Improving P. aeruginosa detection in non-expectorators via breath testing | Dartmouth College (Cystic Fibrosis Foundation) | R1021 | 4/1/2018 - 3/31/2019 | $15,926 |
| KYU SHIK MUN | Patient-derived Pancreatic Duct-on-a-chip to study CFTR Channel Function | Cystic Fibrosis Foundation | Mun CFF Fellowship | 4/1/2018 - 3/31/2019 | $63,100 |
| Anjaparavanda Naren, PHD | Characterization of an inhibitory protein complex for cystic fibrosis therapy | Univ of Tennessee Health Science Center (National Institutes of Health (NIH)) | 18-4808 CHMC | 7/1/2018 - 6/30/2019 | $18,082 |
| Anjaparavanda Naren, PHD | LPA2 receptor-containing complexes in regulating secretory diarrhea | National Institutes of Health (NIH) | R01DK093045 | 7/1/2018 - 6/30/2019 | $351,000 |
| Anjaparavanda Naren, PHD | Transporters and hematopoietic toxicity | St Jude's Children's Hospital (National Institutes of Health (NIH)) | 112128020-7768611 | 7/1/2018 - 6/30/2019 | $28,595 |
| Anjaparavanda Naren, PHD | Inhibition of an Apical cAMP/cGMP Transporter (MRP4) in the Gut induces Diarrhea | National Institutes of Health (NIH) | R01DK080834 | 7/1/2018 - 5/31/2020 | $734,311 |
| Anjaparavanda Naren, PHD John Paul Clancy, MD Jeffrey A Whitsett, MD |
Personalized Cystic Fibrosis Therapy and Research Center | National Institutes of Health (NIH) | P30DK117467 | 8/1/2018 - 6/30/2019 | $782,853 |
| Steven Rheiner, PHD | Exploiting Particle Targeting to Enhance Gene Delivery in CF | Cystic Fibrosis Foundation | RHEINE18F0 | 11/1/2018 - 10/31/2019 | $63,100 |
| Michael Seid, PHD | A CF C3N Care Model of the Future: Proposal for Piloting | Cystic Fibrosis Fdn Therapeutics, Inc | SEID15A0 | 1/1/2017 - 12/31/2019 | $1,477,288 |
| Michael Seid, PHD | Healthy Mind Healthy You: A Dose Finding Study of Mindfulness | Massachusetts General Hospital (Patient-Centered Outcome Research Inst.) | Nierenberg/Massachusetts | 8/1/2018 - 7/31/2019 | $41,768 |
| Christopher Siracusa, MD | Success in Therapies Research Consortium | Cystic Fibrosis Foundation | SIRACU15PE0 | 8/1/2018 - 7/31/2019 | $32,400 |
| Christopher Siracusa, MD | Reducing Stress and Incorporating Wellness Around New Diagnosis in CF | Cystic Fibrosis Foundation | SIRACU18Q1O | 8/1/2018 - 7/31/2019 | $43,200 |
| Vishwaraj Chandrakanth Sontake | Molecular Mechanisms of Pulmonary Fibrosis in Cystic Fibrosis | Cystic Fibrosis Foundation | Sontake CFF | 4/1/2018 - 3/31/2019 | $63,100 |
| Ina St Onge DO | 1st Year Training Grant | Cystic Fibrosis Foundation | STONGE17B0 | 7/1/2018 - 6/30/2019 | $66,250 |
| Laura L Walkup, PHD | Early detection of regional BOS in BMT patients using UTE and 129Xe MRI | National Institutes of Health (NIH) | K99HL138255 | 9/1/2018 - 8/31/2019 | $111,030 |
| Jason C Woods, PHD Raouf S Amin, MD |
UTE MRI to monitor CF lung disease and response to CFTR modulation in young children | National Institutes of Health (NIH) | R01HL131012 | 4/1/2019 - 3/31/2020 | $727,709 |
| Jason C Woods, PHD | A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease | Polarean Inc. (National Institutes of Health (NIH)) | R44HL123299 | 4/1/2018 - 3/31/2019 | $429,395 |
| Jason C Woods, PHD | MRI Phenotyping of Early BPD and Prediction of Outcomes | National Institutes of Health (NIH) | R01HL146689 | 4/1/2019 - 3/31/2020 | $804,339 |
| Assem Ziady, PHD John Paul Clancy, MD |
Targeting Vector Interactome to Enhance CFTR Delivery | National Institutes of Health (NIH) | R21EB023800 | 8/1/2018 - 7/31/2020 | $198,750 |
| Assem Ziady, PHD | Evaluating the Clinical Utility of Serum Biomarkers | Cystic Fibrosis Foundation | ZIADY18P0 | 9/1/2018 - 8/31/2019 | $125,000 |
| Assem Ziady, PHD | Predictive Molecular Markers of Lung Function Decline | National Institutes of Health (NIH) | R01HL142210 | 5/1/2019 - 3/31/2020 | $436,096 |
| Current Year Direct | $11,157,128 | ||||
Annual Industry Award Dollars
| Investigator | Industry Sponsor | Amount |
| Anjaparavanda Naren, PHD | Ironwood Pharmaceuticals, Inc. | $105,000 |
| Gary McPhail, MD | Vertex Pharmaceutical Incorporated | $60,641 |
| Kavisha Arora, PHD | Gilead Sciences, Inc. | $65,000 |
| Sheharyar Durrani, MD | Astrazeneca | $234,342 |
| Total Annual Industry Award Dollars | $464,983 | |
